Video: How do people living with rare diseases feel about clinical trials in 2020?
Faced with the pandemic, the patient community overwhelmingly recognizes the benefits of a decentralized approach to clinical trials
In a year like no other, the Raremark team surveyed 165 community members across four rare conditions to understand drivers and barriers to clinical trial participation.
Watch this video to see what we found:
How do people living with rare diseases feel about clinical trials in 2020?
The Raremark team surveyed 165 community members across four rare conditions.
Here is what we found: 86% of people surveyed are interested in taking part in a clinical trial now or in the future. Among those who said they might consider clinical trials in future, we explored which factors represent the biggest barriers. And we found it’s not just concerns around COVID-19 stopping people from taking part in a trial right now, but also not knowing where to find information about clinical trials.
While the clinical research industry has been experimenting with decentralized and hybrid models for a few years, the COVID-19 pandemic has accelerated this shift. We asked our communities how they felt about these evolving trial types. Given the choice, some participants indicated a preference for receiving the study medication and having monitoring appointments in their own homes, or at a hospital closer to where they live. But even more participants would opt for a combination of clinic visits, at-home visits, and regular appointments at nearby hospitals – underlining the promise of both hybrid and fully decentralized models.
For patients, the attractions of decentralized trials include:
Convenience, through having more of the study take place at home, and less time traveling
And the use of technology, both to communicate with research staff and to have their health monitored
Notably, 87% of participants expressed no concerns at the prospect of a decentralized approach to trials.
While the pandemic has turned many aspects of clinical research upside down, the rare disease community do remain interested in clinical trial participation. Information and education can overcome potential barriers among those expressing a potential interest in trials in future. And survey participants overwhelmingly recognized the potential benefits of decentralized and hybrid models.
If you’re an industry professional and would like to subscribe to updates from our research team, including our research projects and our Rare Opinion blog, fill in your details below and we’ll add you to our mailing list.